The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report

전이성 신세포암에서 Everolimus 사용 후 유발된 간질성 폐렴 1예

  • Lee, So-Ra (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Young-Min (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Jung, Ji-Yun (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Hyung-Joon (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Park, Keon-Woo (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lee, Soon-Il (Department of Internal Medicine, Dankook University College of Medicine)
  • 이소라 (단국대학교 의과대학 내과학교실) ;
  • 김영민 (단국대학교 의과대학 내과학교실) ;
  • 정지연 (단국대학교 의과대학 내과학교실) ;
  • 김형준 (단국대학교 의과대학 내과학교실) ;
  • 김도형 (단국대학교 의과대학 내과학교실) ;
  • 박건우 (단국대학교 의과대학 내과학교실) ;
  • 이순일 (단국대학교 의과대학 내과학교실)
  • Published : 2012.10.01
⟨ Previous Next ⟩

Abstract

Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal cell carcinoma that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as sunitinib and/or sorafenib. Everolimus-induced interstitial pneumonitis is not rare and is sometimes fatal. Due to the potential for pulmonary toxicity due to everolimus, it is recommended that pulmonary complications be periodically evaluated. We report a case of everolimus-associated interstitial pneumonitis in a patient with metastatic renal cell carcinoma.

Everolimus는 전이성 투명세포형 신세포암의 치료제로 쓰인다. 문헌에는 everolimus 사용 후 간질성 폐렴이 발생할 수 있는 것으로 되어 있으나, 국내의 보고는 없었다. 저자들은 전이성 신세포암에서 everolimus 투여한 후 발생한 간질성 폐렴 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

Keywords

References

  1. Shahani R, Kwan KG, Kapoor A. Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). Drug Healthc Patient Saf 2010;2:85-91.
  2. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-852. https://doi.org/10.1016/j.hoc.2011.04.008
  3. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116:4256-4265. https://doi.org/10.1002/cncr.25219
  4. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182: 396-403. https://doi.org/10.1164/rccm.200911-1720OC
  5. Akata K, Yatera K, Ishimoto H, et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011;50:3013-3017. https://doi.org/10.2169/internalmedicine.50.6133
  6. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94: 1569-1575. https://doi.org/10.1093/jnci/94.20.1569
  7. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83. https://doi.org/10.1371/journal.pbio.0000083
  8. Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010;4:91-101.
  9. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133: 528-538. https://doi.org/10.1378/chest.07-0851
  10. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-S23.

Cited by

  1. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer vol.25, pp.4, 2012, https://doi.org/10.1093/annonc/mdu021